A Penn State mice-and-modeling study finds tiny abdominal tensing nudges the brain and may help 'swoosh' cerebrospinal fluid to clear waste tied to dementia. Researchers say human confirmation is needed.

Penn Medicine is using targeted radioactive drugs to shrink tumors in some patients, and new tracers now aim at pancreatic and gastric cancers. Local clinicians say the approach is changing care.

Penn and Temple pulled in three of the nation's top gifts in 2025, including a $120M donation to Penn Medicine and a record $55M gift to Temple's public‑health college.

A new analysis shows Penn’s federal receipts fell to $948M in FY2025, prompting a hiring freeze and 4% spending cuts as leaders brace for more federal policy churn.

Iovance’s Navy Yard plant turns tumors into Amtagvi, the first FDA-approved TIL therapy for melanoma, creating jobs and raising access questions.

A bright fireball flashed over New Jersey and Pennsylvania on Tuesday afternoon; videos circulated and experts say spring often brings an uptick in fireball sightings.

Penn Engineering launched a $200M Futures Fund to seed early‑stage research and spinouts and says it already has sizable early commitments to support climate, AI and biotherapeutics.

PJM says transmission work won’t be done until 2031, clashing with Constellation’s 2027 target to restart the former Three Mile Island unit under a Microsoft power deal.

P. Roy and Diana Vagelos donated $83.9 million to Penn Arts & Sciences — the school’s largest gift — to fund chemistry fellowships and energy research.

Amazon’s cuts and new research show AI is already changing hiring; Philadelphia workers and training programs are racing to adapt. Local entry-level roles are most exposed.

A new ranking places Philadelphia among the nation’s top startup cities, and local funding data and university-led funds suggest investment is beginning to return. The result highlights Philly’s durability and lower costs for founders.

A Penn–Harvard team embedded an ultrathin electronic mesh into pancreatic organoids, boosting cell maturity and glucose responsiveness.

One year after CHOPs first personalized CRISPR case, hospital leaders want to scale the approach into a platform for other rare pediatric diseases. Early signs are promising but major hurdles remain.